Aspira Women’s Health to Announce First Quarter 2022 Financial Results and Host Conference Call on Wednesday, May 11

Rhea-AI Summary

Aspira Women’s Health, Inc. (AWH) will release its financial results for Q1 2022 on May 11, 2022, prior to market opening. A conference call is scheduled for 8:30 AM ET to discuss these results and provide a corporate update. Aspira focuses on innovative testing solutions for women’s health, striving to improve gynecologic outcomes, particularly in ovarian cancer risk assessment. The company has launched Aspira Synergy technology to enhance testing accessibility and is developing new diagnostic products.

Positive

• Launch of Aspira Synergy technology transfer platform to improve test accessibility.
• Development of new diagnostic products, including OVAWatch and EndoCheck.

Negative

• None.

AUSTIN, Texas, April 29, 2022 (GLOBE NEWSWIRE) -- Aspira Women’s Health, Inc. (Nasdaq: AWH), a bioanalytical-based women’s health company, today announced that the company will report its financial results for the first quarter ended March 31, 2022 before the market open on Wednesday, May 11, 2022. Management will also host a conference call with investors to discuss financial results and provide a corporate update at 8:30am Eastern Time. Details for the call are below:

Conference Call & Webcast Details
Date:	Wednesday, May 11
Time:	8:30am ET
Toll Free:	1-844-826-3033
International:	1-412-317-5185
Conference ID:	10166732
Webcast:	https://viavid.webcasts.com/starthere.jsp?ei=1546648&tp_key=889c6ae07f

About Aspira Women’s Health Inc. 
Aspira Women’s Health Inc. is transforming women’s health with the discovery, development, and commercialization of innovative testing options and bio-analytical solutions that help physicians assess risk, optimize patient management, and improve gynecologic health outcomes for women. Aspira Women’s Health is particularly focused on closing the ethnic disparity gap in ovarian cancer risk assessment and developing solutions for pelvic diseases such as pelvic mass risk assessment and endometriosis. OVA1plus^TM combines our FDA-cleared products, OVA1^® and OVERA^®, to detect risk of ovarian malignancy in women with adnexal masses. Aspira GenetiX^TM testing offers both targeted and comprehensive genetic testing options with a gynecologic focus. With over 10 years of expertise in ovarian cancer risk assessment, Aspira Women’s Health is working to deliver a portfolio of pelvic mass products over a patient’s lifetime with our cutting-edge research. The next generation of products in development include OVAWatch^TM and EndoCheck^TM. To improve patient accessibility, Aspira Women’s Health has recently launched our Aspira Synergy^TM technology transfer platform to empower health systems, academics, regional labs, and physician group labs to conduct genetic and specialty tests in-house. Visit our website for more information at www.aspirawh.com.

Investor Relations Contact: 
Ashley R. Robinson  
LifeSci Advisors, LLC  
Tel: 617-430-7577 
Arr@lifesciadvisors.com 

FAQ

When will Aspira Women’s Health report its financial results?

Aspira Women’s Health will report its financial results for Q1 2022 on May 11, 2022.

What time is the conference call for Aspira Women’s Health?

The conference call is scheduled for 8:30 AM ET on May 11, 2022.

What is the focus of Aspira Women’s Health?

Aspira Women’s Health focuses on innovative testing solutions for women’s health and gynecologic outcomes.

How can I access the Aspira Women’s Health webcast?

You can access the webcast at https://viavid.webcasts.com/starthere.jsp?ei=1546648&tp_key=889c6ae07f.